How often do liver enzymes abnormalize with tigecycline?

How often does tigecycline raise liver enzymes?

Tigecycline treatment raises liver enzyme levels in roughly 4–5% of patients overall, but rates climb to 10% or more in some studies and patient groups. Clinical trials reported abnormal liver function tests in 4.9% of patients across pooled data, and 5.2% in pneumonia trials. Rates vary wide because test frequency and definitions of abnormality differ.

Why do rates vary so much between studies?

Rates differ because test frequency and threshold definitions vary. More frequent blood draws catch more transients that would otherwise pass unnoticed. Higher thresholds mean fewer patients qualify as 'abnormal.' Some cohorts include patients who already have mild baseline elevation, so counts of 'new' abnormalities filter out those cases.

What happens if liver enzymes rise during treatment?

When liver enzymes rise during tigecycline use, doctors usually continue monitoring closely. Most elevations prove transient and return to normal after stopping the drug. Severe liver injury remains rare. A few case reports describe acute liver failure, but clinical trial data show almost no withdrawals for liver reasons.

What is the dose relationship to liver enzyme changes?

No consistent dose-response curve appears in published data. Double-dose regimens used for severe infections produce similar rates of enzyme elevation as standard 100 mg loading plus 50 mg every 12 hours. Laboratory monitoring every 2–3 days in high-risk patients suggested no clear escalation of risk at 100 mg daily.

Can other drugs or conditions increase risk?

Concurrent use of other hepatotoxic drugs or baseline liver disease increases risk. Patients who receive tigecycline and vancomycin or piperacillin-tazobactam simultaneously show higher rates of combined liver and kidney marker changes. Baseline liver disease patients exhibit 15–20% abnormal test rates versus 4–5% overall.

When does the patent expire?

Tigecycline's composition-of-matter patent expired in 2014. The active ingredient belongs to the glycylcycline class. Multiple generic manufacturers entered after 2015.